Usher syndrome: an overview

Usher syndrome is the most common hereditary condition that affects both vision and hearing. It is an autosomal recessive condition characterised by retinitis pigmentosa (RP) and bilateral sensorineural hearing loss [1,2]. Usher syndrome is the cause of approximately 10% of...

Development of a modern surgical simulation suite to promote safer ophthalmic surgical training

For trainees, having access to surgical simulation equipment is more important than ever. The authors describe the creation of a bespoke teaching and training suite in Glasgow to help trainees develop their skills and promote surgical excellence. Simulation has become...

Designing ophthalmology services Part 3: How do we address the queues post‑COVID-19?

Part 1 of this series available herePart 2 of this series available here There is going to be enormous demand on ophthalmology services as they start to welcome patients back. The authors explain how modelling can help make the most...

Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference

Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...

Educational concerns and anxiety levels amongst ophthalmology trainees during the COVID-19 pandemic

How concerned are ophthalmology trainees about the present impact and the future consequences of suspended ophthalmic training programmes? Researchers in the West of Scotland investigate. Anxiety, stress and the longer-term stress reaction of burnout often go unrecognised, yet are known...

The Re-humanising Revolution: Breaking the conspiracy of silence

Over the last few years, the mental and emotional wellbeing of those who work in medicine has come under scrutiny. The author introduces a new resource. Working in healthcare has always been stressful but never more so than today. In...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

Setting up successful safe & efficient nurse-led intravitreal injection service: Swindon Model

In September 2019, we organised a training course at Great Western NHS Hospital (GWH), Swindon, which provided presentations, discussions and hands-on wet lab experience on how to perform intravitreal injection using intravitreal assisted device (INVITRIA) for nurses and doctors from...

Retinal prosthetics: science fiction or a vision for the future?

“Is it a fact – or have I dreamt it – that, by means of electricity, the world of matter has become a great nerve, vibrating thousands of miles in a breathless point of time?” – Nathaniel Hawthorne, The House...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

Management of DMO and PDR in 2019

An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...